NASDAQ:AKRX - Nasdaq -
0.09
-0.09 (-51.01%)
The current stock price of AKRX is 0.09 null. In the past month the price decreased by -57.14%. In the past year, price decreased by -97.82%.
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays. Akorn markets its products to retail pharmacies, ophthalmologists, optometrists, physicians, veterinarians, hospitals, clinics, wholesalers, distributors, group purchasing organizations, and government agencies. Their strategy is focused on continuing to strengthen our leadership position in the development and marketing of specialized generic and branded pharmaceuticals, over-the-counter (`OTC`) drug products and animal health products.
Akorn Inc
1925 WEST FIELD COURT SUITE 300
LAKE FOREST IL 60045
CEO: Douglas S. Boothe
Phone: 847-279-6100
The current stock price of AKRX is 0.09 null. The price decreased by -51.01% in the last trading session.
The exchange symbol of Akorn Inc is AKRX and it is listed on the Nasdaq exchange.
AKRX stock is listed on the Nasdaq exchange.
Akorn Inc (AKRX) has a market capitalization of 11.98M null. This makes AKRX a Nano Cap stock.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AKRX does not pay a dividend.
The PE ratio for Akorn Inc (AKRX) is 0.64. This is based on the reported non-GAAP earnings per share of 0.14 and the current share price of 0.09 null. Check the full fundamental report for a full analysis of the valuation metrics for AKRX.
ChartMill assigns a fundamental rating of 4 / 10 to AKRX. While AKRX is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months AKRX reported a non-GAAP Earnings per Share(EPS) of 0.14000000000000004. The EPS increased by 122.58% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -55.64% | ||
ROA | -38.88% | ||
ROE | N/A | ||
Debt/Equity | -1.1 |
ChartMill assigns a Buy % Consensus number of 60% to AKRX. The Buy consensus is the average rating of analysts ratings from 1 analysts.